Beta Bionics Announces Upsized $234.6 Million IPO, Concurrent $17 Million Private Placement

San Diego – January 31, 2025 – Cooley advised Beta Bionics, a pioneering leader in the development of advanced diabetes management solutions, on its upsized $234.6 million initial public offering (IPO) and concurrent $17 million private placement. The IPO was for 13,800,000 shares of common stock at a price to the public of $17 per share, including the full exercise of the underwriters’ option to purchase 1,800,000 additional shares (consisting of 475,000 shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus). Beta Bionics’ common stock began trading on the Nasdaq Global Market on January 30, 2025, under the ticker symbol “BBNX.” BofA Securities, Piper Sandler and Leerink Partners acted as lead bookrunners for the offering. Stifel acted as a bookrunner, and Lake Street Capital Markets acted as co-manager for the offering.

In addition, Beta Bionics sold 1,000,000 shares of its common stock in a concurrent private placement to one of its existing investors at the IPO price of $17 per share. The aggregate gross proceeds to Beta Bionics from the IPO, including the full exercise of the underwriters’ option to purchase 475,000 additional shares from Beta Bionics, and the concurrent private placement – before deducting underwriting discounts and commissions, placement agent fees, and other offering and private placement expenses payable by Beta Bionics – were approximately $229.1 million.

Partners Carlos Ramirez, Mark Weeks and Charlie Kim led the Cooley team advising Beta Bionics.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.